This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Marc Buyse, MSc, MBA; Anne Zeleniuch-Jacquotte, MD; Thomas C. Chalmers, MD
Harvard School of Public Health Dana Farber Cancer Institute Boston

JAMA. 1989;261(7):988.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

We could not have dreamed of clearer confirmation for the title of our article than these two letters, one claiming that randomized clinical trials of adjuvant chemotherapy in colorectal cancer are no longer needed because the benefit associated with treatment has been established clearly and the other claiming that no meaningful benefit has ever been, nor will soon be, demonstrated. We take issue with both claims and plead for a less glamorous, but more honest, acknowledgment of uncertainty.

As potential patients with this disease, we find it ethically worrying that Dr Clouse would deny us the potential benefit of adjuvant therapy while Dr Bruckner would impose on us an as yet unproved therapy. We agree with the authors of the editorial¹ that the most rational attitude, and therefore that most consistent with ethics, is to perform further clinical trials in this disease. Such trials do not . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?